Review Article
Metastatic Bladder Cancer: A Review of Current Management
Table 2
Summary of literature related to second-line chemotherapy and targeted therapies for metastatic bladder cancer.
| | Chemotherapy | Targeted Therapies | | Bellmunt et al. [14] | Bellmunt et al. [14] | Joly et al. [15] | Fechner et al. 2006 [16] | Fechner et al. 2006 [16] | Sweeney et al. [17] | Hussain et al. [18] | Wulfing et al. [19] | Hahn et al. [20] | Rosenberg et al. [21] | Gomez-Abuin et al. [22] |
| | Chemotherapy regime | Vinflunine + Best supportive care | Best supportive care alone | Paclitaxel | Gem-Pac 3 weekly regime | Gem-Pac 2 weekly regime | Pemetrexed | Trastuzumab plus Pac, Carbo, and Gem | Lapatinib | GC + Bevacizumab | Bortezomib | Bortezomib | | Response Rate (%) | 8.6 | 0 | 9 | 50 | 38 | 27.7 | 70 | 3 | 67 | 0 | 0 | | Complete Response rate (%) | 0 | 0 | 2 | 50 | 7 | 6.4 | 11.4 | 0 | 17 | 0 | 0 | | Median time to progressive disease (months) | | | 3 | 11 | 6 | | 9.3 | 2 | | 1.4 | 1.9 | | Median survival (months) | 6.9 | 4.3 | 7 | 13 | 9 | 9.6 | 14 | 4.1 | 19.1 | 5.7 | 3.5 | | Toxicity | | | | | | | | | | | | Grade 3 or 4
Neutropenia (%) | 50 | 2.7 | | 36 | 23 | 4.3 | 86.4 | | 35 | 0 | 0 | | Neutropenic sepsis or febrile neutropenia (%) | 6 | 0 | 4 | | | | 40.9 | | 2 | 0 | 0 | Drug-related
deaths (%) | | | | | | | 5 | 1.7 | 7 | 0 | 0 |
|
|
